Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pathogenesis and Immunity

Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice

Kanta Subbarao, Josephine McAuliffe, Leatrice Vogel, Gary Fahle, Steven Fischer, Kathleen Tatti, Michelle Packard, Wun-Ju Shieh, Sherif Zaki, Brian Murphy
Kanta Subbarao
1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Ksubbarao@niaid.nih.gov
Josephine McAuliffe
1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leatrice Vogel
1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Fahle
2Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Fischer
2Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen Tatti
3Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Packard
3Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wun-Ju Shieh
3Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sherif Zaki
3Infectious Disease Pathology Activity, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Murphy
1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.78.7.3572-3577.2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Kinetics and dose-response of SARS-CoV replication in the respiratory tract of mice. The graphs show the mean titers of virus detected on the indicated days in the lower respiratory tract (A) and upper respiratory tract (B) of four BALB/c mice per group following intranasal administration of the indicated doses of SARS-CoV. Error bars associated with each data point indicate standard errors, and the dotted line indicates the lower limit of detection of virus in 10% (wt/vol) (lungs) and 5% (wt/vol) (nasal turbinates) suspensions.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Histopathology, immunohistochemistry, and in situ hybridization of mouse lung tissues harvested on day 2 following infection. (A) Focal and mild peribronchiolar mononuclear inflammatory infiltrate. Hematoxylin and eosin stain; magnification, ×158. (B) SARS-CoV antigens in multiple bronchiolar epithelial cells. Immunoalkaline phosphatase staining, naphthol-fast red substrate with light hematoxylin counterstain; original magnification, ×158. (C and D) SARS-CoV nucleic acids in multiple bronchiolar epithelial cells. Immunoalkaline phosphatase staining, naphthol-fast red substrate with light hematoxylin counterstain. Original magnification: C, ×100; D, ×250.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Detection of viral nucleic acid in lung homogenates by RT-PCR. RNA extracted from serial 10-fold dilutions of lung homogenates obtained from mice that received passive transfers of immune or nonimmune serum was subjected to RT-PCR. For each dilution, the cycle number at which amplicons were detected is indicated. SARS-CoV nucleic acid was not detected at 45 cycles (dotted line) in lung homogenates from three mice (×, ▵, and □) that received passive transfers of immune serum but was detected in the virus stock (•) and also when virus was added exogenously to lung homogenates from mice that had received immune serum (⧫) or nonimmune serum (▪).

Tables

  • Figures
  • TABLE 1.

    Primary infection with SARS-CoV protects mice from subsequent challengea

    Primary infection inoculum (TCID50)Challenge dose (TCID50)Neutralizing antibody titerMean virus titer (log10 TCID50/g) ± SEb
    LungsNasal turbinates
    1051051:25*1.6 ± 0.13*≤1.8 ± 0*
    1031:49*≤1.5 ± 0c**≤1.8 ± 0d*
    0 (mock)105≤1:86.5 ± 0.185.4 ± 0.30
    103≤1:44.5 ± 1.024.5 ± 0.18
    • ↵ a SARS-CoV challenge virus was administered intranasally 28 days following primary infection. Geometric mean neutralizing antibody titers in serum collected 28 days after primary infection were determined.

    • ↵ b *, P < 0.05 versus mock-infected control; **, P = 0.058 versus mock-infected control.

    • ↵ c Virus was not detected; this value represents the lower limit of detection of infectious virus in a 10% suspension.

    • ↵ d Virus was not detected; this value represents the lower limit of detection of infectious virus in a 5% suspension.

  • TABLE 2.

    Passive transfer of immune serum protects naïve mice from replication of challenge virus in the respiratory tract

    Expt no. and dose of SARS-CoV (TCID50)Passively transferred serumaNeutralizing antibody titer in serumbMean prechallenge neutralizing anti- body titer in re- cipient miceVirus replication in challenged mice
    LungsNasal turbinates
    No. of mice infected/no. testedMean virus titerc ± SENo. of mice infected/no. testedMean virus titer ± SE
    1 (103)Immune1:2841:280/3≤1.5 ± 0d2/33.2 ± 0.72
    Nonimmune≤1:4≤1:42/33.9 ± 1.212/32.4 ± 0.32
    2 (104)Immune, undiluted1:1,0241:2310/3≤1.8 ± 0e*1/32.0 ± 0.17*
    Immune, 1:10 dilution1:2741:221/32.0 ± 0.172/33.3 ± 0.73
    Nonimmune≤1:4≤1:43/37.3 ± 0.143/35.6 ± 0.55
    • ↵ a Serum (200 μl) pooled from immunized or uninfected mice was administered to recipient mice by intraperitoneal injection in experiment 1, and 500 μl of the indicated serum preparation was administered to mice in experiment 2.

    • ↵ b Titer of antibody that neutralized infectivity of 100 TCID50 of SARS-CoV.

    • ↵ c Virus titers are expressed as log10 TCID50 per gram of tissue. *, P < 0.05 versus nonimmune control.

    • ↵ d Virus not detected; this value represents the lower limit of detection of infectious virus in a 10% suspension.

    • ↵ e Virus not detected; this value represents the lower limit of detection of infectious virus in a 5% suspension.

PreviousNext
Back to top
Download PDF
Citation Tools
Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice
Kanta Subbarao, Josephine McAuliffe, Leatrice Vogel, Gary Fahle, Steven Fischer, Kathleen Tatti, Michelle Packard, Wun-Ju Shieh, Sherif Zaki, Brian Murphy
Journal of Virology Mar 2004, 78 (7) 3572-3577; DOI: 10.1128/JVI.78.7.3572-3577.2004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice
Kanta Subbarao, Josephine McAuliffe, Leatrice Vogel, Gary Fahle, Steven Fischer, Kathleen Tatti, Michelle Packard, Wun-Ju Shieh, Sherif Zaki, Brian Murphy
Journal of Virology Mar 2004, 78 (7) 3572-3577; DOI: 10.1128/JVI.78.7.3572-3577.2004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Viral
Immunization, Passive
lung
SARS Virus
Severe Acute Respiratory Syndrome

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514